Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Protara Therapeutics, Inc. (PRTO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update"
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/02/2023 8-K Quarterly results
04/28/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development"
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/08/2023 10-K Annual Report for the period ended December 31, 2022
03/08/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
02/14/2023 SC 13G/A ORBIMED ADVISORS LLC reports a 6% stake in Protara Therapeutics, Inc.
02/10/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
01/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer"
01/05/2023 8-K Investor presentation
Docs: "PROTARA THERAPEUTICS, INC. CORPORATE PRESENTATION, JANUARY 2023"
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
07/18/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
04/27/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/09/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2022 10-K Annual Report for the period ended December 31, 2021
03/09/2022 8-K Quarterly results
02/14/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2022 SC 13G/A Rock Springs Capital Management LP reports a 0% stake in Protara Therapeutics, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy